UNSPSC 51172154: Vetrabutine or vetrabutine hydrochloride

This classification denotes an antispasmotic agent with the molecular formulas C20H27NO2 and C20H27NO2.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers I3E2J32F37 and 54IF66RP20, the base comppound being chemically known as 1-(3,4-dimethoxyphenyl)-1-dimethylamino-4-phenylbutane but generally known as vetrabutine, which bears US NIH Compound Identifier 111122. European Medicines Agency schedules Vetrabutine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB00046MIG and SUB05093MIG.

UNSPSC 51172154 Vetrabutine or vetrabutine hydrochloride is a Commodity code that reflects state and local procurement of pharmaceutical products and related testing services, though recent opportunities tagged under this code diverge significantly from the narrow chemical compound the code nominally describes. The Collin County Community Supervision and Corrections Department RFP 2026-327, posted July 9, 2026 with proposals due July 23, 2026, requests offender specimen collection and drug testing services including immunoassay screening with LC/MS/MS or GC/MS confirmation, oral fluid and hair testing, and electronic result reporting — a services contract rather than a chemical purchase. The Texas Health and Human Services Commission RFI HHS0017013, posted April 3, 2026, solicits vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between state pharmacy benefit programs and manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, establishes contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. The code shows activity from state health agencies, county criminal justice departments, and cooperative purchasing consortia.

Recent opportunities span Texas (Collin County and HHS Commission) and the Minnesota-Oregon regional cooperative, with the Collin County RFP representing the most concrete near-term procurement—a $600,000 estimated value contract with a two-year term commencing September 1, 2026 and anticipated award August 10, 2026, structured as multiple-award RFP with pricing on a per-test basis across three service models and annual testing volume of approximately 25,031 tests. The MMCAP pharmaceutical RFP covers generic products and OTC items through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with evaluation weighted 75 percent on price competitiveness and specific focus on cGMP and Drug Supply Chain Security Act compliance. The HHS Commission RFI is preliminary market intelligence without award value or timeline rather than a formal competitive solicitation. The code shows little alignment with vetrabutine hydrochloride procurement specifically; state and local buyers tagged under this code are primarily acquiring broad drug testing services, generic pharmaceutical supply agreements, and pharmacy program infrastructure rather than the specific alkaloid compound the code name indicates.